Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time
Conditions
Interventions
EN3409
Locations
57
United States
Parkway Medical Center
Birmingham, Alabama, United States
Horizon Research Group, Inc
Mobile, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Global Research, LLC
Anaheim, California, United States
Synergy Clinical Research Center of Escondido
Escondido, California, United States
RX Clinical Research, Inc.
Garden Grove, California, United States
Start Date
December 1, 2012
Primary Completion Date
October 1, 2014
Completion Date
November 1, 2014
Last Updated
October 18, 2018
NCT07153471
NCT07351968
NCT06747494
NCT06381791
NCT07327931
NCT06906939
Lead Sponsor
BioDelivery Sciences International
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions